An article published by Merlin researchers from UNIPD has recently been published in the “Leukemia” journal. The piece is entitled “Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1” (Author(s): Zanotti L, Angioni R, Calì B, Soldani C, Ploia C, Moalli F, Gargesha M, D’Amico G, Elliman S, Tedeschi G, Maffioli E, Negri A, Zacchigna S, Sarukhan A, Stein JV, Viola A) and appears in the May issue. The article deals with the impact of MSC on immunity and inflammation and identifies TIMP-1 as a novel biomarker for MSC-based therapy. You can access the article here.
- RT @AutoCRAT2020: #MyFirstTweet! Greetings all! We are a @EU_H2020 research project! Please follow us if you are interested in #celltherapy… Time ago 3 Days via Twitter for iPhone
- RT @FP7Merlin: Up to 56 patients are being recruited to take part in the @FP7Merlin trial, which will investigate the safety and efficacy o… Time ago 13 Days via Twitter for iPhone
- RT @DrDeeds3: Orbsen are hiring a senior GMP production scientist in Birmingham! #celltherapy @Orbsen t.co/J1dmbLjLFv Time ago 67 Days via Twitter for iPhone
Follow @fp7merlin on twitter.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.